update

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…

4 months ago

Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements and Implementation of Cease Trade Order

August 08, 2025 18:28 ET  | Source: Aja Health and Wellness Inc. Not for dissemination in the United States of…

4 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and…

4 months ago

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted…

4 months ago

Cango Inc. Announces July 2025 Bitcoin Production and Mining Operations Update

HONG KONG, Aug. 5, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company") today published its Bitcoin production…

4 months ago

Sirona Biochem Update to Shareholders on Financial Status and Operations

August 01, 2025 16:30 ET  | Source: Sirona Biochem Corp. VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona…

4 months ago

NYSE Content Advisory: Pre-market update + Ambiq raises $96 million in IPO

NEW YORK, July 30, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

4 months ago

NYSE Content Advisory: Pre-market update + Wall Street anticipates Fed’s next move

NEW YORK, July 29, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

4 months ago

NYSE Content Advisory: Pre-market update + U.S. & EU reach trade deal

NEW YORK, July 28, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

4 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

July 25, 2025 16:05 ET  | Source: atai Life Sciences Initial results demonstrate numerical improvement of cognitive and functional measures…

4 months ago